<DOC>
	<DOCNO>NCT00006136</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether arginine butyrate without epoetin alfa stimulate gamma-globin chain production degree decrease anemia result hematologic improvement patient thalassemia intermedia . II . Determine whether proportional increase gamma-globin synthesis mRNA improvement nonalfa alfaglobin chain imbalance least 10 % baseline correlate improve hematologic response patient treat regimen . III . Determine whether decrease hemolysis , assayed decrease LDH , compare baseline level correlate improved hematologic response patient treat regimen . IV . Determine whether particular genotype responsive others therapy patient . V. Determine whether baseline epoetin alfa level , gender , and/or baseline reticulocyte count ( percent circulate nucleated erythroblast ) correlate improve hematologic response patient treat regimen .</brief_summary>
	<brief_title>Phase II Study Arginine Butyrate With Without Epoetin Alfa Patients With Thalassemia Intermedia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This multicenter study . Patients receive arginine butyrate IV 6-14 hour day 1-5 week 1-4 7-10 . Patients receive maintenance arginine butyrate IV 6-14 hour day 1-4 week 13 , 15 , 17 , 19 , 21 , 23 , 25 . Patients medical contraindication ( e.g. , paraspinal extramedullary hematopoiesis , hypertension , poorly control congestive heart failure ) may continue therapy . Patients receive arginine butyrate IV 6-14 hour day 1-4 week 27 , 29 , 31 , 33 , 35 , 37 , 39 epoetin alfa intramuscularly ( IM ) subcutaneously ( SC ) three time weekly week 27-40 . Patients may continue receive epoetin alfa IM SC alone three time weekly week 41-52 . Patients severe anemia ( hemoglobin le 7 g/dL ) may receive epoetin alfa alone week 1-12 arginine butyrate induction therapy . Patients complete therapy week 26 follow every 2 week 2 month . Patients complete therapy week 40 follow monthly 2 month .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Butyric Acid</mesh_term>
	<mesh_term>Arginine butyrate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis thalassemia intermedia hemoglobin great 10 g/dL Two beta thalassemia mutation Must undergone prior splenectomy palpable spleen Prior/Concurrent Therapy At least 3 month since prior red blood cell transfusion Patient Characteristics Performance status : SWOG 02 Hematopoietic : No severe iron overload ferritin great 5,000 ng/mL Hepatic : Normal hepatic function No active hepatitis Renal : Normal renal function Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must willing vascular access place No viral disease No contraindication study compliance</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>thalassemia intermedia</keyword>
</DOC>